![conference banner](/images/conference-banner.jpeg)
Abstract
An understanding of the historical paths that have lead to our current state of knowledge in the field of platelet studies can be both illuminating and inspiring. Considering that the existence and function of platelets were initially described just barely over 100 years ago it is exciting to recognize how far our knowledge has advanced in such a relatively short period of time. Within 20 years of Giulio Bizzozero's definitive description of blood platelets investigators began to develop tests that could quantitate the relationship between platelets, hemostasis and bleeding, and these tests have continued to be refined ever since. At the same time, and well before the role of platelets and antiplatelet agents in cardiovascular disease was appreciated, several clinicians started using aspirin for the prevention of heart attacks. All three of these paths of research - platelet biology, platelet function testing and antiplatelet therapies - all converge on what is arguably one of the most important questions in clinical medicine today: how to best prevent arterial thrombosis. For the current and future pioneers of platelet research an understanding of how we got to where we are today will hopefully allow for a clearer and inspired vision of where we will go next.
Keywords: Platelet, aggregometry, aspirin, history, bleeding time, platelet adhesiveness, light transmittance aggregometry, salicyclates, early medical therapy
Current Drug Targets
Title: Historical Observations on the Discovery of Platelets, Platelet Function Testing and the First Antiplatelet Agent
Volume: 12 Issue: 12
Author(s): Steven R. Steinhubl
Affiliation:
Keywords: Platelet, aggregometry, aspirin, history, bleeding time, platelet adhesiveness, light transmittance aggregometry, salicyclates, early medical therapy
Abstract: An understanding of the historical paths that have lead to our current state of knowledge in the field of platelet studies can be both illuminating and inspiring. Considering that the existence and function of platelets were initially described just barely over 100 years ago it is exciting to recognize how far our knowledge has advanced in such a relatively short period of time. Within 20 years of Giulio Bizzozero's definitive description of blood platelets investigators began to develop tests that could quantitate the relationship between platelets, hemostasis and bleeding, and these tests have continued to be refined ever since. At the same time, and well before the role of platelets and antiplatelet agents in cardiovascular disease was appreciated, several clinicians started using aspirin for the prevention of heart attacks. All three of these paths of research - platelet biology, platelet function testing and antiplatelet therapies - all converge on what is arguably one of the most important questions in clinical medicine today: how to best prevent arterial thrombosis. For the current and future pioneers of platelet research an understanding of how we got to where we are today will hopefully allow for a clearer and inspired vision of where we will go next.
Export Options
About this article
Cite this article as:
R. Steinhubl Steven, Historical Observations on the Discovery of Platelets, Platelet Function Testing and the First Antiplatelet Agent, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635858
DOI https://dx.doi.org/10.2174/138945011797635858 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cell-based Therapies in Cardiovascular Diseases: From Pathophysiology
to Clinical Outcomes
Current Pharmaceutical Design Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation
Current Medicinal Chemistry Thienopyridines in Percutaneous Coronary Interventions: Standard Procedures and High Risk Subsets
Current Pharmaceutical Design Enhanced Butyrylcholinesterase Activity may be the Common Link in Triggering Low-Grade Systemic Inflammation and Decrease in Cognitive Function in Diabetes Mellitus and Alzheimers disease
Current Nutrition & Food Science Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Current Medicinal Chemistry Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
Current Neurovascular Research The Relationship Between Inflammation and the Anticoagulant Pathway: The Emerging Role of Endothelial Nitric Oxide Synthase (eNOS)
Current Pharmaceutical Design Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits
Vascular Disease Prevention (Discontinued) A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease
Current Alzheimer Research Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology